Navigation Links
Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
Date:7/24/2012

BLUE BELL, Pa., July 24, 2012 /PRNewswire/ -- Relmada Therapeutics, a clinical-stage company developing novel therapies for the treatment of chronic pain today announced the initial closing of $3 million in gross proceeds in a Series A financing for which Laidlaw & Company (UK) Ltd. is the exclusive placement agent.  Noteholders BioAdvance and Ben Franklin Technology Partners of Southeastern Pennsylvania, as well as, equity investor Wonpung Mulsan Co., Ltd, have converted their existing liens into the Series A Convertible Preferred Stock.

The initial Series A proceeds will be used to continue the development of LevoCap, a proprietary once-a-day extended release dosage form of the potent opioid levorphanol in a tamper resistant delivery system and for general corporate activities. 

"This impressive response from new investors and existing stakeholders speaks to the potential of our diversified portfolio of drug candidates to address the significant unmet medical need in chronic pain," said Sergio Traversa, CEO of Relmada. "Based on this successful initial offering, we anticipate completing additional formulation development, GMP manufacturing and pharmacokinetic studies required to initiate Phase III studies by mid-2013.  The additional funds expected from the on-going Series A financing will be used to further develop our other products: MepiGel, d-methadone and BuTab," added Traversa.

Relmada's lead product, LevoCap is intended to add a new tool to treat chronic pain where non-opioids or other opioids do not provide adequate relief.  Unlike most other opioids, levorphanol, the active ingredient in LevoCap modulates pain through both opioid pathways and noradrenergic pathways, thereby providing pain relief through multiple mechanisms in a single molecule. Levorphanol has also been shown to partially reverse analgesic tolerance to morphine and may therefore benefit patients who are tolerant to the analgesic
'/>"/>

SOURCE Relmada Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing in medical imaging ... vital sign monitoring in ICU to 3D skull printing analysis for Neurosurgery, ONYX ... clinical decisions with simultaneous access to high precision medical images and electronic health ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... equipment, to creating professional commercial video content, to analysis of athletic performance. Producing ... events that go by too quickly to process with the naked eye. ...
(Date:9/1/2015)... ... September 02, 2015 , ... Spirax Sarco , the leader in products ... Spirax Sarco Anytime. This platform, offering unique online ordering capabilities, is only available ... Log on to Spirax Sarco Anytime and within minutes you can be making ...
(Date:9/1/2015)... 2015 Prostate cancer is the second ... men. One in seven men will be diagnosed ... are diagnosed annually. That said, not every diagnosis ... new technique, MRI Fusion Biopsy, to more accurately ... only the affected areas and monitoring areas ...
Breaking Biology Technology:Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Spirax Sarco Announces New Features to Anytime Platform 2September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4
... , , , , SEATTLE, ... at the Rodman & Renshaw 11th Annual Healthcare Conference on Wednesday, September 9th at ... Hotel. , , The conference will also be webcast live with ... www.celltherapeutics.com . , , , ...
... COLUMBIA, Md., Sept. 2 ACell, Inc. is announcing its participation ... , The conference will be held September 9, ... in New York City. James DeFrancesco, Chief Executive Officer and President, ... at 9:10 AM (EDT) in the Hubbard Room. The presentation is ...
... BERLIN, September 2 , - Asset Purchase Agreement ... and NeoBenz(R) Micro, , Intendis GmbH, which ... agreement to acquire two prescription dermatology product lines,from SkinMedica, Inc., a ... Both Desonate(R) and NeoBenz(R) Micro are currently marketed in the ...
Cached Biology Technology:ACell's CEO to Present at Rodman & Renshaw's 2009 Annual Global Investment Conference 2Bayer Acquires Two Prescription Dermatology Product Lines From SkinMedica in the U.S. 2Bayer Acquires Two Prescription Dermatology Product Lines From SkinMedica in the U.S. 3
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:8/4/2015)... Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today reported ... 2015. Highlights: , Second quarter contract revenue ... 2014 , Adjusted contract margins of ... $0.22, including a $0.05 decrease in EPS from royalties in the ... million "We are very pleased to present another ...
(Date:7/31/2015)... SHENZHEN , Kina, 31. juli 2015 ... ) bliver afholdt af BGI fra den 22. - 25. ... Konferencen fejrer sin 10-års fødselsdag i år. ... verdens mest indflydelsesrige årlige møder på ,omik,-feltet, og er ... forsamlinger. ICG-10 fokuserer på nylige gennembrud ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... MA. Wed. March 6, 2013 New work from ... Hospital, Harvard University, MIT, and Yale University expands the ... known as a T helper 17 or Th17 cell ... of immune responses. By figuring out how these cells ...
... JOLLA, CA Scientists at the Salk Institute for ... only allow plants to adapt to various environments, but could ... Published March 6 in Nature , the findings ... throughout the world, their epigenomic makeup is as varied as ...
... All too often, stress turns addiction recovery into ... scientists with insight that might allow them develop a ... Neuron pinpoints the neural basis for stress-related ... advance could accelerate progress toward a medicine that prevents ...
Cached Biology News:Circuitry of cells involved in immunity, autoimmune diseases exposed 2Circuitry of cells involved in immunity, autoimmune diseases exposed 3Circuitry of cells involved in immunity, autoimmune diseases exposed 4Circuitry of cells involved in immunity, autoimmune diseases exposed 5Hidden layer of genome unveils how plants may adapt to environments throughout the world 2Hidden layer of genome unveils how plants may adapt to environments throughout the world 3Study pinpoints, prevents stress-induced drug relapse in rats 2Study pinpoints, prevents stress-induced drug relapse in rats 3
XA7 B6...
... motor and ballscrew technologies, the ... solutions that include all the ... motors., , XY and ... high-flex cabling for power, signals, ...
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
...
Biology Products: